Ország: Kanada
Nyelv: angol
Forrás: Health Canada
APIXABAN
TEVA CANADA LIMITED
B01AF02
APIXABAN
2.5MG
TABLET
APIXABAN 2.5MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0153051001; AHFS:
APPROVED
2022-09-20
_ _ _Teva-Apixaban Tablets _ _Page 1 of 81_ PRODUCT MONOGRAPH Pr TEVA-APIXABAN Apixaban tablets 2.5 mg and 5 mg Teva Standard Anticoagulant Teva Canada Limited 30 Novopharm Court Toronto, Ontario M1B 2K9 Date of Initial Approval: January 21, 2019 Date of Revision: September 16, 2022 Submission Control No: 266721 _ _ _Teva-Apixaban Tablets _ _Page 2 of 81_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................20 DOSAGE AND ADMINISTRATION ..............................................................................25 OVERDOSAGE ................................................................................................................33 ACTION AND CLINICAL PHARMACOLOGY ............................................................34 STORAGE AND STABILITY ..........................................................................................40 SPECIAL HANDLING INSTRUCTIONS .......................................................................40 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................40 PART II: SCIENTIFIC INFORMATION ...............................................................................41 PHARMACEUTICAL INFORMATION ..........................................................................41 CLINICAL TRIALS ......................... Olvassa el a teljes dokumentumot